



MEN

FIRST CANCER SITE
LARYNX

LARYNX
POOL AIRTUM 1976-2010, MEN:

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

LARINGE
POOL AIRTUM 1976-2010, UOMINI:

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
No. of subjects alive at interval beginning ▶	22869		24038		24038		22869		19291		9642		4135		22869	24038
Person-years ▶	123654		127548		3895		17553		54580		33079		18441		123654	127548
SECOND CANCER SITE	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
ALL SITES, BUT SKIN AND LARYNX	3863	1.57	4225	1.67	362	5.46	402	1.33	1689	1.67	1075	1.54	697	1.54	11.35	13.32
HEAD AND NECK	213	1.91	225	1.96	12	3.50	32	2.07	89	1.82	58	1.93	34	2.01	0.82	0.86
ORAL CAVITY	129	5.03	136	5.15	7	9.00	24	6.82	54	4.84	31	4.44	20	5.02	0.84	0.86
PHARYNX	84	3.56	88	3.62	4	5.47	8	2.42	35	3.36	27	4.25	14	4.00	0.49	0.50
LARYNX	0	0.00	1	0.02	1	0.52	0	0.00	0	0.00	0	0.00	0	0.00	-0.50	-0.49
OESOPHAGUS	124	4.47	162	5.68	38	47.15	12	3.29	54	4.57	45	5.90	13	2.81	0.78	1.05
STOMACH	206	1.35	211	1.34	5	1.14	16	0.81	89	1.39	53	1.25	48	1.82	0.43	0.42
COLON RECTUM	341	1.00	346	0.99	5	0.56	28	0.68	151	1.09	106	1.09	56	0.87	0.01	-0.02
COLON	227	0.98	231	0.97	4	0.66	18	0.66	99	1.06	73	1.10	37	0.83	-0.04	-0.05
RECTUM	114	1.06	115	1.04	1	0.34	10	0.74	52	1.16	33	1.08	19	0.98	0.05	0.03
LIVER	139	1.36	146	1.39	7	2.51	18	1.42	62	1.47	40	1.39	19	1.03	0.30	0.32
GALLBLADDER	29	1.11	30	1.12	1	1.44	1	0.32	9	0.85	11	1.49	8	1.61	0.02	0.03
PANCREAS	75	1.12	78	1.13	3	1.67	9	1.10	31	1.13	20	1.05	15	1.20	0.06	0.07
LUNG	1408	3.08	1602	3.41	194	15.02	147	2.51	638	3.33	389	3.06	234	2.93	7.69	8.87
SKIN MELANOMA	28	0.82	28	0.80	0	0.00	2	0.48	7	0.50	11	1.14	8	1.26	-0.05	-0.05
MESOTHELIOMA	9	0.68	10	0.74	1	2.94	0	0.00	5	0.94	2	0.53	2	0.79	-0.03	-0.03
KAPOSI SARCOMA	6	1.18	6	1.15	0	0.00	1	1.55	3	1.42	1	0.71	1	1.09	0.01	0.01
SOFT TISSUE	1	0.12	1	0.12	0	0.00	0	0.00	0	0.00	1	0.42	0	0.00	-0.06	-0.06
BONE	1	0.44	1	0.43	0	0.00	0	0.00	1	1.03	0	0.00	0	0.00	-0.01	-0.01
BREAST	4	0.76	4	0.74	0	0.00	1	1.53	2	0.92	0	0.00	1	1.04	-0.01	-0.01
PROSTATE	408	0.85	418	0.85	10	0.86	33	0.62	165	0.88	118	0.85	92	0.95	-0.57	-0.56
TESTIS	3	1.22	4	1.57	1	11.62	1	2.60	2	1.77	0	0.00	0	0.00	0.00	0.01
KIDNEY AND RENAL PELVIS	85	1.07	92	1.13	7	3.26	12	1.23	32	0.98	22	0.99	19	1.33	0.05	0.08
BLADDER AND URINARY TRACT	465	1.66	489	1.70	24	3.15	49	1.42	211	1.83	127	1.61	78	1.52	1.50	1.58
URINARY BLADDER	453	1.69	477	1.73	24	3.29	49	1.48	207	1.88	120	1.59	77	1.57	1.50	1.58
URINARY TRACT	12	1.00	12	0.98	0	0.00	0	0.00	4	0.82	7	2.06	1	0.44	0.00	0.00
BRAIN AND CENTRAL NERVOUS SYSTEM	24	0.82	24	0.80	0	0.00	0	0.00	12	0.97	4	0.50	8	1.63	-0.04	-0.05
THYROID	13	1.20	50	4.47	37	120.06	6	4.26	5	1.09	1	0.33	1	0.54	0.02	0.30
HODGKIN LYMPHOMA	4	0.81	6	1.17	2	12.63	0	0.00	4	1.83	0	0.00	0	0.00	-0.01	0.01
NON-HODGKIN LYMPHOMA	85	1.21	89	1.23	4	2.09	10	1.15	34	1.17	26	1.32	15	1.18	0.12	0.13
MYELOMA	22	0.68	22	0.66	0	0.00	4	1.01	8	0.60	7	0.76	3	0.50	-0.08	-0.09
LEUKAEMIAS	57	1.02	61	1.06	4	2.58	6	0.86	22	0.95	14	0.89	15	1.49	0.01	0.03
LYMPHOID LEUKAEMIAS	17	0.63	21	0.75	4	5.27	3	0.87	4	0.35	6	0.79	4	0.84	-0.08	-0.05
MYELOID LEUKAEMIAS	35	1.40	35	1.37	0	0.00	3	0.98	14	1.38	8	1.13	10	2.14	0.08	0.07
OTHER LEUKAEMIAS	5	1.30	5	1.26	0	0.00	0	0.00	4	2.47	0	0.00	1	1.54	0.01	0.01
OTHER AND ILL DEFINED SITES	113	0.89	121	0.93	8	2.33	14	0.90	53	1.02	19	0.53	27	1.14	-0.11	-0.07

■ Decrease/Difetto ○ Observed cases ■ SIR Standardized Incidence Ratio ■ EAR Excess Absolute Risk
■ Increase/Eccesso ○ Casi osservati ■ Rapporto standardizzato di incidenza ■ Eccesso assoluto di rischio



WOMEN

FIRST CANCER SITE
LARYNXLARYNX
POOL AIRTUM 1976-2010, WOMEN:

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

LARINGE
POOL AIRTUM 1976-2010, DONNE:

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
No. of subjects alive at interval beginning ▶	2155		2289		2289		2155		1805		922		378		2155	2289
Person-years ▶	11649		12017		368		1644		5142		3112		1752		11649	12017
SECOND CANCER SITE	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
ALL SITES, BUT SKIN AND LARYNX	233	1.79	257	1.91	24	6.32	17	1.00	101	1.84	70	1.95	45	1.97	8.80	10.21
HEAD AND NECK	13	7.64	14	8.00	1	19.92	2	8.94	6	8.34	3	6.40	2	6.94	0.97	1.02
ORAL CAVITY	6	6.71	7	7.61	1	39.39	0	0.00	4	10.78	1	4.02	1	6.21	0.44	0.51
PHARYNX	7	18.61	7	18.06	0	0.00	2	38.85	2	12.19	2	19.41	1	17.38	0.57	0.55
LARYNX	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.04	-0.04
OESOPHAGUS	6	9.51	8	12.32	2	110.17	0	0.00	1	3.83	3	17.20	2	17.28	0.46	0.61
STOMACH	11	1.47	12	1.56	1	4.48	1	1.02	4	1.29	4	1.96	2	1.50	0.30	0.36
COLON RECTUM	34	1.70	35	1.70	1	1.76	5	1.97	13	1.58	8	1.44	8	2.19	1.20	1.20
COLON	18	1.26	18	1.22	0	0.00	3	1.66	7	1.19	4	1.00	4	1.50	0.31	0.27
RECTUM	16	2.83	17	2.93	1	6.09	2	2.73	6	2.55	4	2.56	4	4.01	0.89	0.93
LIVER	6	1.75	6	1.70	0	0.00	0	0.00	2	1.43	4	4.21	0	0.00	0.22	0.21
GALLBLADDER	2	0.74	2	0.72	0	0.00	0	0.00	1	0.89	1	1.34	0	0.00	-0.06	-0.07
PANCREAS	7	1.36	7	1.32	0	0.00	0	0.00	2	0.96	2	1.39	3	3.00	0.16	0.14
LUNG	73	8.71	82	9.52	9	38.60	3	2.87	33	9.58	20	8.55	17	10.95	5.55	6.11
SKIN MELANOMA	2	0.85	2	0.82	0	0.00	1	3.22	0	0.00	1	1.53	0	0.00	-0.03	-0.04
MESOTHELIOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	-0.03
KAPOSI SARCOMA	2	11.94	2	11.61	0	0.00	0	0.00	2	29.03	0	0.00	0	0.00	0.16	0.15
SOFT TISSUE	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.05	-0.05
BONE	1	6.88	1	6.68	0	0.00	1	50.62	0	0.00	0	0.00	0	0.00	0.07	0.07
BREAST	39	1.16	44	1.27	5	4.97	2	0.44	19	1.31	15	1.63	3	0.55	0.46	0.78
CERVIX UTERI	3	1.72	3	1.67	0	0.00	0	0.00	1	1.28	1	2.20	1	4.03	0.11	0.10
CORPUS UTERI	4	0.64	4	0.62	0	0.00	0	0.00	3	1.11	1	0.59	0	0.00	-0.19	-0.20
OVARY	2	0.48	2	0.47	0	0.00	0	0.00	1	0.56	0	0.00	1	1.47	-0.19	-0.19
KIDNEY AND RENAL PELVIS	1	0.31	1	0.30	0	0.00	0	0.00	1	0.76	0	0.00	0	0.00	-0.19	-0.19
BLADDER AND URINARY TRACT	6	1.22	6	1.19	0	0.00	1	1.63	3	1.49	1	0.73	1	1.10	0.09	0.08
URINARY BLADDER	6	1.32	6	1.28	0	0.00	1	1.75	3	1.61	1	0.79	1	1.18	0.12	0.11
URINARY TRACT	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	-0.03
BRAIN AND CENTRAL NERVOUS SYSTEM	1	0.52	1	0.51	0	0.00	0	0.00	0	0.00	0	0.00	1	3.01	-0.08	-0.08
THYROID	2	0.87	6	2.54	4	57.44	0	0.00	1	0.99	1	1.59	0	0.00	-0.02	0.30
HODGKIN LYMPHOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	-0.03
NON-HODGKIN LYMPHOMA	4	0.82	4	0.79	0	0.00	1	1.60	3	1.47	0	0.00	0	0.00	-0.08	-0.09
MYELOMA	1	0.44	1	0.43	0	0.00	0	0.00	0	0.00	1	1.59	0	0.00	-0.11	-0.11
LEUKAEMIAS	6	1.90	6	1.85	0	0.00	0	0.00	1	0.77	3	3.44	2	3.52	0.24	0.23
LYMPHOID LEUKAEMIAS	3	2.14	3	2.08	0	0.00	0	0.00	0	0.00	3	7.74	0	0.00	0.14	0.13
MYELOID LEUKAEMIAS	2	1.34	2	1.30	0	0.00	0	0.00	0	0.00	0	0.00	2	7.29	0.04	0.04
OTHER LEUKAEMIAS	1	3.95	1	3.83	0	0.00	0	0.00	1	9.64	0	0.00	0	0.00	0.06	0.06
OTHER AND ILL DEFINED SITES	7	0.76	8	0.84	1	3.80	0	0.00	4	1.06	1	0.39	2	1.15	-0.19	-0.12

■ Decrease/Difetto ○ Observed cases ■ SIR Standardized Incidence Ratio ■ EAR Excess Absolute Risk
■ Increase/Eccesso ○ Casi osservati ■ Rapporto standardizzato di incidenza ■ Eccesso assoluto di rischio